Hong Kong watchdog investigates Cloudbreak Pharma for ‘rigged’ IPO, suspends its shares

Hong Kong’s Securities and Futures Commission (SFC) has directed the stock exchange to suspend trading of US-based biote

ch firm Cloudbreak Pharma pending an investigation into its US$78 million initial public offering (IPO) last year. “The SFC has serious concerns that Cloudbreak’s initial public offering may have been...

via South China Morning Post